NEW YORK – A team led by University of Kansas researchers has launched a National Institutes of Health-funded validation study to see if a microfluidic cell-capture and phenotyping assay could be used instead of invasive bone marrow aspirates to identify early cases of hematological cancers.
Led by Steven Soper, a chemistry and mechanical engineering professor at the University of Kansas, the team aims to identify acute lymphoblastic leukemia (ALL) biomarkers in circulating leukemia cells (CLCs).